Evidence for the Polymorphic Oxidation of Debrisoquine in the Thai Population

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1990 Feb 1

PMID 2306417

Citations 4

Authors

S Wanwimolruk

P Patamasucon

E J Lee

Affiliations

Soon will be listed here.

Abstract

Debrisoquine polymorphism has been studied extensively in Caucasian populations. The prevalence of the poor metaboliser phenotype is 3-10% in European and American Caucasian populations but appears to be very low in Asian populations. This study was carried out to determine the metabolic oxidation status in 173 Thai subjects. Phenotyping was performed using the metabolic ratio (MR) calculated as the 0-8 h urinary output of debrisoquine/0-8 h urinary output of 4-hydroxydebrisoquine after oral administration of 10 mg debrisoquine hemisulphate. Two subjects (1.2%) were phenotyped as poor metabolisers; they had MR values of 13.17 and 92.04. The incidence of the poor metaboliser phenotype of debrisoquine oxidation of 1.2% seems to be lower in the Thai population compared with that in various Caucasian populations.

Citing Articles

Cytochrome P 2D6 polymorphism in eastern Indian population.

Dhuya M, Pal M, Hazra A, Chatterjee S, Gogtay N Indian J Pharmacol. 2020; 52(3):189-195.

PMID: 32874001 PMC: 7446679. DOI: 10.4103/ijp.IJP_530_17.

Genetic polymorphism of CYP2D6 in a keralite (South India) population.

Abraham B, Adithan C, Shashindran C, Vasu S, Alekutty N Br J Clin Pharmacol. 2000; 49(3):285-6.

PMID: 10718787 PMC: 2014911. DOI: 10.1046/j.1365-2125.2000.00142-2.x.

Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Wanwimolruk S, Thou M, Woods D Br J Clin Pharmacol. 1995; 40(2):166-9.

PMID: 8562301 PMC: 1365178. DOI: 10.1111/j.1365-2125.1995.tb05772.x.

Polymorphism of debrisoquine oxidation in New Zealand Caucasians.

Wanwimolruk S, Denton J, Ferry D, Beasley M, Broughton J Eur J Clin Pharmacol. 1992; 42(3):349-50.

PMID: 1577057 DOI: 10.1007/BF00266364.

References

Eichelbaum M, Spannbrucker N, Steincke B, DENGLER H . Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979; 16(3):183-7. DOI: 10.1007/BF00562059. View

Lou Y, Ying L, Bertilsson L, Sjoqvist F . Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 1987; 2(8563):852-3. DOI: 10.1016/s0140-6736(87)91034-8. View

Lee E, Ang S . Measurement of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography. J Pharm Biomed Anal. 1987; 5(4):435-9. DOI: 10.1016/0731-7085(87)80052-3. View

KALOW W . Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982; 7(5):373-400. DOI: 10.2165/00003088-198207050-00001. View

Eichelbaum M . Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982; 7(1):1-22. DOI: 10.2165/00003088-198207010-00001. View

KALOW W, Otton S, KADAR D, Endrenyi L, Inaba T . Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can J Physiol Pharmacol. 1980; 58(9):1142-4. DOI: 10.1139/y80-173. View

Nakamura K, Goto F, Ray W, McALLISTER C, Jacqz E, Wilkinson G . Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985; 38(4):402-8. DOI: 10.1038/clpt.1985.194. View

Kupfer A, Preisig R . Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984; 26(6):753-9. DOI: 10.1007/BF00541938. View

Evans D, Mahgoub A, Sloan T, Idle J, Smith R . A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980; 17(2):102-5. PMC: 1048511. DOI: 10.1136/jmg.17.2.102. View

10.

Islam S, Idle J, Smith R . The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. Xenobiotica. 1980; 10(11):819-25. DOI: 10.3109/00498258009033812. View

11.

Arias T, Jorge L, Lee D, Barrantes R, Inaba T . The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers. Clin Pharmacol Ther. 1988; 43(4):456-65. DOI: 10.1038/clpt.1988.58. View

12.

Mahgoub A, Idle J, Dring L, Lancaster R, Smith R . Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977; 2(8038):584-6. DOI: 10.1016/s0140-6736(77)91430-1. View

13.

Mahgoub A, Idle J, Smith R . A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica. 1979; 9(1):51-6. DOI: 10.3109/00498257909034703. View

14.

Brosen K . Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br J Clin Pharmacol. 1986; 22(4):415-9. PMC: 1401149. DOI: 10.1111/j.1365-2125.1986.tb02911.x. View